Year: 2026
Type: article
Study design: Case Report
Abstract: Dermatomyositis (DM) is an autoimmune inflammatory myopathy that may rarely be drug induced. Statin-induced dermatomyositis (DIDM) is uncommon, with only few atorvastatin-related cases described in the literature. We present a case of a 62-year-old Hispanic woman who developed progressive proximal muscle weakness, myalgias, and joint discomfort shortly after initiating atorvastatin therapy. Despite discontinuation of the statin, her symptoms persisted and were accompanied by new cutaneous lesions. Laboratory evaluation revealed marked elevation of muscle enzymes, and subsequent skin biopsy revealed lymphocytic perivascular and perifollicular infiltrated with dermal mucin. Autoimmune serologies were negative, and malignancy screening was unremarkable. Treatment with systemic corticosteroids and mycophenolate mofetil resulted in gradual improvement. This report underscores the diagnostic challenges in differentiating statin-induced rhabdomyolysis from inflammatory myopathy, highlights the potential for rapid onset of dermatomyositis after statin exposure, and expands the limited literature on DIDM in Hispanic patients. By sharing this case, we aim to raise awareness among clinicians of this rare but clinically significant association, emphasizing the need for early recognition, histopathology, and malignancy screening to optimize outcomes. LEARNING POINTS: Statin-induced dermatomyositis is a rare immune-mediated complication that may mimic rhabdomyolysis early in its presentation.Lack of clinical or biochemical improvement after statin withdrawal and intravenous hydration should raise suspicion for inflammatory myopathy.Cutaneous findings, seronegative myositis profile, and skin biopsy features are key to distinguishing dermatomyositis from necrotizing autoimmune myopathy.
DOI: 10.12890/2026_006098
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $323
OpenAlex ID: W7127400892